# Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

Source: https://onco.cc/institutions/cams-hematology/  
OnCo record `cams-hematology` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

China's national blood disease hospital in Tianjin is where the CD19 binder behind the CAR-T inati-cel was made; it runs large leukaemia and myelodysplastic syndrome registries and early-phase trials of domestic bispecifics and cell therapies.

## Summary

The national centre for haematology within CAMS, with the State Key Laboratory of Experimental Hematology; origin of the CNCT19 CAR-T (inaticabtagene autoleucel, approved 2023 for adult B-ALL with Juventas), large leukaemia and myelodysplastic syndrome registries and early-phase trials of domestic bispecifics and cell therapies.

## Fields

- Kind: Institution
- Last checked: 2026-09-10
- Also known as: Blood Diseases Hospital CAMS; 中国医学科学院血液病医院; IH-CAMS
- Tags: china
- City: Tianjin, CN
- Type: hospital
- Website: https://www.chinablood.com.cn/

## Sources

- Official website: https://www.chinablood.com.cn/

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- drugs: [Inaticabtagene autoleucel](https://onco.cc/drugs/inaticabtagene-autoleucel/)
- institutions: [Cancer Hospital, Chinese Academy of Medical Sciences](https://onco.cc/institutions/cams-cancer-hospital/)
- people: [Tao Cheng](https://onco.cc/people/tao-cheng/)

---
JSON: https://onco.cc/api/v1/entities/cams-hematology.json